Non-Sponsored Content
Hydroxyurea FDA approved for the reduction in frequency of painful crises and blood transfusions in paediatric sickle cell anemia patients
By: News Feed | Last updated: 21st December 2017 | In: US FDA Onc\Haem Approvals
Article Keywords
AddMedica, blood transfusion, FDA, hydroxyurea, paediatric, painful crises, sickle cell anaemia, Siklos
On 21 December the FDA granted regular approval to hydroxyurea (Siklos®, Addmedica) for the reduction in frequency of painful crises and the need for blood transfusions in paediatric sickle cell anaemia patients ≥2 years of age with recurrent moderate to severe painful crises.
Disclaimer
This article is not medical advice. Patients should seek personal assessment by a licenced specialist. Physicians are recommended to read the full publication(s) as cited in the article before making medical decisions. This article does not supersede nor replace the published article(s).
© Copyright 2018 MediPaper Medical Communications Ltd.
YOU MAY ALSO LIKE
Venetoclax plus azacitidine, decitabine, or low-dose cytarabine FDA approved in elderly AML patients
© Copyright 2018 MediPaper Medical Communications Ltd.
Leave a Reply
Want to join the discussion?Feel free to contribute!